Holmgren and Gilgeous-Alexander each score 22 as Thunder take 2-0 lead over Lakers in West semis

OKLAHOMA CITY (AP) — Shai Gilgeous-Alexander isn't scoring the way he usually does, but the Oklahoma City Thunder are still winning the way they normally do.

Gilgeous-Alexander, the reigning NBA MVP, averaged 31.1 points during the regular season. In the Western Conference semifinals against the Los Angeles Lakers, he’s averaging 19 points and taking only 14 shots per game.

Oklahoma City has still won the first two games by an average of 18 points. Gilgeous-Alexander and Chet Holmgren each scored 22 points, and the defending champion Thunder beat the Lakers 125-107 on Thursday night.

Ajay Mitchell, starting in place of injured Jalen Williams, is averaging 19 points on 50% shooting in the series for Oklahoma City.

“I think the coaching staff does a good job at just getting all of us ready,” said Mitchell, a second-year guard. "And we have a lot of competitors. Like, everyone’s a competitor on our team. So every time the lights are bright, everyone’s ready to go.”

Holmgren is the leading scorer for the Thunder in the best-of-seven series with 23 points per game. The 2026 All-Star also is averaging 10.5 rebounds and 2.5 blocks.

Jared McCain, a midseason acquisition from the Philadelphia 76ers, barely played in the first round against Phoenix but has averaged 15 points and made 8 of 10 3-pointers in the series.

“He goes in there, stays in character, stays aggressive," Thunder coach Mark Daigneault said. "He’s going to shoot the next shot. He makes the right plays, plays inside the team. He competes defensively, has had good defensive possessions for us. And he was huge tonight. You need that in a playoff series.”

The Lakers again were without scoring champion Luka Doncic, who is out indefinitely with a strained left hamstring. They also were missing forward Jarred Vanderbilt, the reserve forward who dislocated the pinkie on his right hand during the second quarter of Game 1. The Lakers also had three players finish with five fouls, limiting their aggressiveness late in the game.

Los Angeles guard Austin Reaves, who struggled with his shot in Game 1, scored 31 points on 10-for-16 shooting in Game 2. LeBron James, coming off a 27-point effort in Game 1, followed that up with 23.

With the Lakers up 63-61 early in the third quarter, Gilgeous-Alexander got tied up with Reaves and was called for his fourth foul. Upon review, it was upgraded to a flagrant 1 for Gilgeous-Alexander's follow through. Oklahoma City's Alex Caruso was called for a technical foul as the situation was being sorted out.

Gilgeous-Alexander left the game with the Lakers up 65-61, but the Thunder rallied and took control without him. On a fast break, Holmgren found a trailing Jaylin Williams, who hit a 3-pointer and was fouled. His free throw put the Thunder up 85-74.

The Thunder outscored the Lakers 32-15 while Gilgeous-Alexander was out in the third quarter to take a 93-80 lead into the fourth.

“It was amazing," Gilgeous-Alexander said. “They strung together stops, they’re playing the right way offensively and things are going their way. Full confidence in those guys. They know how to win basketball games. And we've proven that. They’ve proven that no matter who’s on the floor, they know how to get the job done. And they just did it again tonight.”

The Lakers cut Oklahoma City's lead to five in the fourth quarter before the Thunder pulled away again.

Los Angeles will host Game 3 on Saturday.

“We just stuck with it,” Holmgren said. “It’s the game of basketball. It’s not always going to go your way. It’s about how you respond. And this team has proven many times that we know how to respond. And we did so tonight.”

AP NBA: https://apnews.com/hub/NBA

Oklahoma City Thunder's Chet Holmgren (7) shoots over Los Angeles Lakers' Austin Reaves (15) in the second half of Game 2 in a second-round NBA basketball playoffs series Thursday, May 7, 2026, in Oklahoma City. (AP Photo/Nate Billings)

Oklahoma City Thunder guard Ajay Mitchell, front, works for a shot as Los Angeles Lakers' Austin Reaves, rear, defends in the second half of Game 2 in a second-round NBA basketball playoffs series Thursday, May 7, 2026, in Oklahoma City. (AP Photo/Nate Billings)

Los Angeles Lakers' LeBron James stands on the court in the second half of Game 2 in a second-round NBA basketball playoffs series against the Oklahoma City Thunder Thursday, May 7, 2026, in Oklahoma City. (AP Photo/Nate Billings)

Oklahoma City Thunder guard Shai Gilgeous-Alexander (2) drives to the basket past Los Angeles Lakers' Deandre Ayton (5) and LeBron James, rear, in the second half of Game 2 in a second-round NBA basketball playoffs series Thursday, May 7, 2026, in Oklahoma City. (AP Photo/Nate Billings)

Oklahoma City Thunder center Chet Holmgren (7) works to the basket against Los Angeles Lakers forward Rui Hachimura (28) in the second half of Game 2 in a second-round NBA basketball playoffs series Thursday, May 7, 2026, in Oklahoma City. (AP Photo/Nate Billings)

TOKIO--(BUSINESS WIRE)--may. 8, 2026--

Un grupo de médicos y científicos de la India y Japón ha publicado un descubrimiento científico pionero que esclarece el mecanismo de cicatrización exitosa de la estenosis uretral mediante la terapia celular BEES-HAUS. Este logro histórico en medicina regenerativa, que demuestra seguridad y eficacia clínicas, es el primero de su tipo en el que se utilizó un enfoque híbrido que combina dos grupos de células epiteliales bucales autólogas,un grupo cultivado en 2D y otro en 3D en un sustrato de Festigel, para el tratamiento de la estenosis uretral. El efecto paracrino del IGF-1 producido por las células cultivadas en 2D y el injerto de las células cultivadas en 3D en Festigel, que cubren la herida de la uretrotomía, reparando conjuntamente el defecto urotelial, ha sido publicado en Frontiers in Urology. Aunque modesta, esta proeza es una primicia mundial tanto en términos de ingeniería de tejidos in vitro como de beneficios clínicos por la cicatrización in vivo, ya que restaura la integridad urotelial y supone un gran avance por su potencial de ofrecer una buena calidad de vida sin recurrencia de la estenosis a pacientes con problemas de micción, opinaron los investigadores.

Este comunicado de prensa trata sobre multimedia. Ver la noticia completa aquí: https://www.businesswire.com/news/home/20260506926989/es/

Las tecnologías de ingeniería de tejidos para crear órganos en el laboratorio, como la uretra, ya se conocen y se han descrito. Sin embargo, encontrar una solución a largo plazo que evite la recurrencia de la estenosis uretral masculina sigue siendo un reto. La dilatación con balón o la uretrotomía DVIU exponen el tejido suburotelial a la orina, lo que desencadena un proceso inflamatorio que causa esponjofibrosis y la recurrencia de la estenosis. El recubrimiento de la herida de la uretrotomía, para restaurar la integridad urotelial de la uretra afectada por la estenosis, que actualmente se logra mediante una plastia BMG con una lámina de tejido bucal autólogo, en el procedimiento BEES-HAUS se realiza mediante un trasplante celular para estenosis de segmentos cortos. El trasplante celular de un solo paso aún más simplificado “ BHES-HAUS ” que no requiere cultivo celular en laboratorio y que ofrece resultados alentadores, ha sido aceptado para una presentación interactiva en la reunión de la Asociación Americana de Urología, AUA 2026.

La reacción inflamatoria de la uretra provocada por el cateterismo, la intervención quirúrgica o una infección es diferente en cada persona, y algunas desarrollan estenosis uretral. Para predecir los riesgos y desarrollar mejores estrategias de tratamiento, se han puesto en marcha las siguientes investigaciones pioneras:

BEES-HAUS, la tecnología que ha sido aprobada en Japón de conformidad con la Ley de Seguridad de la Medicina Regenerativa, GN Corporation y Global Niche Corp., de EE. UU. está abierta a la concesión de licencias y la transferencia de tecnología de BHES-HAUS para su aplicación clínica una vez obtenida su aprobación a nivel mundial.

El texto original en el idioma fuente de este comunicado es la versión oficial autorizada. Las traducciones solo se suministran como adaptación y deben cotejarse con el texto en el idioma fuente, que es la única versión del texto que tendrá un efecto legal.

Vea la versión original en businesswire.com:https://www.businesswire.com/news/home/20260506926989/es/

CONTACT: Samuel JK Abraham

info@gncorporation.com

KEYWORD: DISTRICT OF COLUMBIA NORTH AMERICA UNITED STATES ASIA PACIFIC INDIA JAPAN

INDUSTRY KEYWORD: HEALTH SURGERY HEALTH TECHNOLOGY RESEARCH SCIENCE BIOTECHNOLOGY

SOURCE: GN Corporation Co Ltd

Copyright Business Wire 2026.

PUB: 05/08/2026 02:39 AM/DISC: 05/08/2026 02:39 AM

http://www.businesswire.com/news/home/20260506926989/es

Urethral stricture starts with narrowing of a short segment of urethral lumen. At early stages, it is managed by balloon dilatation or DVIU Urethrotomy. The open urethrotomy wound after dilatation or DVIU has to heal from the edges of the wound, which may take a longer time. In BEES-HAUS cell therapy, the cell transplant having proven successful engraftment, covering the urethrotomy wound, yielding clinical safety and efficacy may be considered be included in the treatment guidelines after validation. Its simplified version, the BHES-HAUS (Buccal epithelium Hashed and Encapsulated in Scaffold—Hybrid Approach to Urethral Stricture) accomplished in one-go without need for cell culture in a lab, works on similar principles. After long term follow-up, BHES-HAUS minimally invasive approach may be worth combining with DVIU and balloon dilatation, as it may be able to provide longer duration of recurrence-free, good quality of life without need for intermittent self-catheterization.